Lotery, Andrew http://orcid.org/0000-0001-5541-4305
Clemens, Andreas http://orcid.org/0000-0001-6192-1557
Tuli, Raman
Xu, Xun
Shimura, Masahiko
Nardi, Marco
Ziemssen, Focke http://orcid.org/0000-0002-3873-0581
Dunger-Baldauf, Cornelia
Tadayoni, Ramin
,
Funding for this research was provided by:
Novartis Pharma AG, Basel, Switzerland
Novartis Pharma AG, Basel Switzerland
Article History
Received: 14 December 2020
Revised: 13 July 2021
Accepted: 15 July 2021
First Online: 29 July 2021
Competing interests
: AL: Consultant for Novartis and Allergan. AC: Shareholder and full-time employee of Novartis Pharma AG. RT: Consultant for Roche; has received grants from Novartis, Roche and Apellis. XX: Nothing to disclose. MS: Nothing to disclose. MN: Consultant for Alcon and Santen; has lectured for Allergan; has performed trials or received grants from Novartis, Bayer, Roche, Sensimed, Ivantis, Formycon and Coronis GmbH. FZ: Consultant for Alimera, Allergan, Bayer, Boheringer Ingelheim, MSD, Novartis, Novonordisk, Oxurion, Optos and Roche; has lectured for Allergan, Bayer, CME Health, Novartis and ODOS. CD-B: Shareholder and part-time employee of Novartis Pharma AG. RT: Consultant for Novartis, Roche, Genentech, Bayer, Allergan, Oculis, Thea, Alcon, B + L, Zeiss, Moria and Cutting Edge. The aforementioned disclosures for all authors do not alter our adherence to journal policies on sharing data and materials.